(Q62025724)
Statements
A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM (English)
0 references
29 August 2018
0 references
7 October 2019
0 references
99
0 references
18 year
0 references
70 year
0 references